10x Genomics price target lowered to $15 from $18 at Barclays
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
Hosted on MSN2d
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
10x Genomics Inc (TXG) Q4 2024 Earnings Call Highlights: Navigating Challenges with Strategic ...
Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...
10x, Harvard settle genomics patent dispute with Vizgen during trial
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...
10x Genomics: Q4 Earnings Snapshot
PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...
Seattle's Parse Biosciences lands another legal victory in patent dispute
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
10x Genomics, Inc.: 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...